Showing results (521-530 of 565) with videos related to
Sort By:
Pageof 57
The New Phytologist|June 24, 2025
Why are non-native plants successful? Consistently fast economic traits and novel origin jointly explain abundance across US ecoregionsDana M Blumenthal, Jeffrey Diez, Ian Pearse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmEmily Y Jen, Xin Gao, Liang Li, et al.The Lancet. Oncology|January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJulia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2018
Clinical Development of Novel Drug-Radiotherapy CombinationsSaif S Ahmad, Marka R Crittenden, Phuoc T Tran, et al.Oncotarget|October 21, 2014
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumorsGideon M Blumenthal, Joell J Gills, Marc S Ballas, et al.Ecology|October 8, 2022
Stronger fertilization effects on aboveground versus belowground plant properties across nine U.S. grasslandsAdrienne B Keller, Christopher A Walter, Dana M Blumenthal, et al.Cell Chemical Biology|October 22, 2024
Quinoline-based compounds can inhibit diverse enzymes that act on DNAJujun Zhou, Qin Chen, Ren Ren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level AnalysesKelly J Norsworthy, Xin Gao, Chia-Wen Ko, et al.The Lancet. Oncology|December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.Pageof 57